Published in Med Mol Morphol on June 01, 2006
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med (2010) 2.54
The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis (2012) 1.67
Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression. Mol Brain (2015) 1.12
Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ (2011) 1.05
Mutant TP53 posttranslational modifications: challenges and opportunities. Hum Mutat (2014) 0.91
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res (2015) 0.88
Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells. J Cancer Res Clin Oncol (2010) 0.84
Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53. Cancer Biol Ther (2011) 0.81
Met acts through Abl to regulate p53 transcriptional outcomes and cell survival in the developing liver. J Hepatol (2012) 0.79
Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells. BMB Rep (2014) 0.78
Modelling the p53/p66Shc Aging Pathway in the Shortest Living Vertebrate Nothobranchius Furzeri. Aging Dis (2015) 0.78
FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15. Oncotarget (2015) 0.78
p53 regulation upon genotoxic stress: intricacies and complexities. Mol Cell Oncol (2014) 0.76
Bioinformatics study of cancer-related mutations within p53 phosphorylation site motifs. Int J Mol Sci (2014) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
p53 mutations in human cancers. Science (1991) 31.96
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science (1996) 19.48
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
The p53 tumour suppressor gene. Nature (1991) 14.49
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 13.46
p53: puzzle and paradigm. Genes Dev (1996) 13.16
Functional inactivation of genes by dominant negative mutations. Nature (1987) 13.12
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev (2001) 12.46
The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell (1997) 10.52
Signaling to p53: breaking the MDM2-p53 circuit. Cell (1998) 8.63
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev (1998) 7.46
The p53 pathway. J Pathol (1999) 6.79
Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer (2004) 6.67
Identification of p53 as a sequence-specific DNA-binding protein. Science (1991) 6.60
Presence of a potent transcription activating sequence in the p53 protein. Science (1990) 6.38
Regulation of the specific DNA binding function of p53. Cell (1992) 6.16
Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev (2000) 5.90
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev (2000) 5.72
p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell (2000) 5.64
Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem (2000) 5.58
Decision making by p53: life, death and cancer. Cell Death Differ (2003) 5.52
p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A (1994) 5.49
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 5.47
Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem (2001) 5.43
Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31
Recruitment of p300/CBP in p53-dependent signal pathways. Cell (1997) 5.10
p53: death star. Cell (2000) 4.77
Human p53 gene localized to short arm of chromosome 17. Nature (1986) 4.67
Regulation of p53 downstream genes. Semin Cancer Biol (1998) 4.22
Gain of function mutations in p53. Nat Genet (1993) 4.19
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol (1992) 3.68
Structural aspects of the p53 protein in relation to gene evolution. Oncogene (1990) 3.64
Inhibition of DNA replication factor RPA by p53. Nature (1993) 3.58
TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer (1992) 3.50
Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J (1999) 3.46
Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (1992) 3.41
Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A (1994) 3.36
Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci U S A (1994) 3.30
Regulation of p53 function and stability by phosphorylation. Mol Cell Biol (1999) 3.24
Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A (1999) 3.13
Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J (1999) 3.08
Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res (1994) 3.02
ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet (1998) 3.01
Small peptides activate the latent sequence-specific DNA binding function of p53. Cell (1995) 2.96
Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev (2004) 2.94
Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem (1997) 2.81
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U S A (1990) 2.77
Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol (1990) 2.73
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
Localization of gene for human p53 tumour antigen to band 17p13. Nature (1986) 2.56
DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J (1999) 2.50
Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature (1995) 2.47
Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene (1999) 2.43
The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol Cell Biol (1993) 2.37
The transactivator proteins VP16 and GAL4 bind replication factor A. Cell (1993) 2.32
Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A (1996) 2.30
Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J (1993) 2.21
The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci U S A (1986) 2.18
Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J Biol Chem (1993) 2.15
The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci U S A (1993) 2.11
Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J Biol Chem (2000) 2.08
Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell (1994) 2.06
Oligomerization of oncoprotein p53. J Virol (1988) 1.98
Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A (1993) 1.96
Regulation of p53 responses by post-translational modifications. Cell Death Differ (2003) 1.95
A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell (2001) 1.88
Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. Proc Natl Acad Sci U S A (1992) 1.86
Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev (1996) 1.86
How p53 binds DNA as a tetramer. EMBO J (1998) 1.82
The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene (2001) 1.80
The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene (1997) 1.79
Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene (1996) 1.75
CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res (1997) 1.70
Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry (1997) 1.66
Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J Biol Chem (2004) 1.63
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev (1996) 1.63
Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol (1998) 1.62
p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem (1999) 1.55
Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol (2001) 1.54
Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem (2000) 1.53
Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res (2000) 1.50
Conformation-dependent phosphorylation of p53. Proc Natl Acad Sci U S A (1997) 1.49
Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol Cell (2004) 1.44
High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol (1996) 1.42
Post-translational modification of p53. Semin Cancer Biol (1994) 1.38
The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol Cell Biol (1997) 1.34
Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem (1996) 1.31
p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol (1997) 1.31
Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J Biol Chem (1995) 1.26
DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. Nature (1999) 1.25
Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen. J Virol (1988) 1.24
Serine phosphorylation in the NH2 terminus of p53 facilitates transactivation. Cancer Res (1995) 1.24
'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene (1998) 1.17
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res (2004) 1.73
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res (2007) 1.61
Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet (2012) 1.59
Application of 5-aminolevulinic acid-mediated photodynamic diagnosis to robot-assisted laparoscopic radical prostatectomy. Urology (2013) 1.47
Cigarette smoke-induced acute eosinophilic pneumonia accompanied with neutrophilia in the blood. Intern Med (2002) 1.42
SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones. J Biol Chem (2001) 1.40
HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci (2005) 1.28
Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol (2006) 1.21
HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res (2004) 1.13
Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med (2009) 1.12
Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Res (2009) 1.12
Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease. Med Mol Morphol (2007) 1.12
A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1. Clin Exp Metastasis (2008) 1.07
Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest (2009) 1.04
Idiopathic non-specific interstitial pneumonia: as an "autoimmune interstitial pneumonia". Respir Med (2005) 1.04
Zeb1-mediated T-cadherin repression increases the invasive potential of gallbladder cancer. FEBS Lett (2008) 1.04
Expression levels of PEPT1 and ABCG2 play key roles in 5-aminolevulinic acid (ALA)-induced tumor-specific protoporphyrin IX (PpIX) accumulation in bladder cancer. Photodiagnosis Photodyn Ther (2013) 1.04
Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model. J Mol Cell Cardiol (2009) 1.03
Photodynamic diagnosis of positive margin during radical prostatectomy: preliminary experience with 5-aminolevulinic acid. Int J Urol (2011) 1.03
Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci (2009) 1.02
Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer. Cancer (2011) 1.02
Augmented autocrine bone morphogenic protein (BMP) 7 signaling increases the metastatic potential of mouse breast cancer cells. Clin Exp Metastasis (2012) 1.02
Immunohistochemical analysis of invasive micropapillary carcinoma pattern in four cases of gastric cancer. Med Mol Morphol (2013) 1.02
Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer (2005) 1.01
The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer. Oncol Rep (2010) 1.01
Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis. Lab Invest (2006) 1.00
Pathological findings of bronchiectases caused by Mycobacterium avium intracellulare complex. Respir Med (2003) 0.99
Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastasis (2009) 0.99
Primary gastric small cell carcinoma: report of a case and review of the literature. Med Mol Morphol (2005) 0.98
Early-phase neutrophilia in cigarette smoke-induced acute eosinophilic pneumonia. Intern Med (2003) 0.98
CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells. Int J Cancer (2012) 0.98
Skeletrophin, a novel ubiquitin ligase to the intracellular region of Jagged-2, is aberrantly expressed in multiple myeloma. Am J Pathol (2005) 0.97
Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias. Med Mol Morphol (2007) 0.95
IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility. Hum Mol Genet (2012) 0.95
cDNA cloning and developmental expression of murine carbonic anhydrase-related proteins VIII, X, and XI. Brain Res Mol Brain Res (2002) 0.95
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol (2007) 0.95
Inflammatory pseudotumor of the liver: report of a case diagnosed by needle biopsy. Hepatol Res (2003) 0.95
Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. Oncol Rep (2004) 0.95
Immunohistochemical and electron microscopic studies of a case of duodenal gangliocytic paraganglioma. Med Mol Morphol (2009) 0.95
Thymic mucosa-associated lymphoid tissue lymphoma with immunoglobulin-storing histiocytosis in Sjögren's syndrome. Pathol Int (2010) 0.94
A case of salivary gland-type mixed tumor of the lung differentiating toward type II alveolar epithelial cells in glandular components with a literature review. Virchows Arch (2002) 0.93
Differential gene-expression profiling in the leukemia cell lines derived from indolent and aggressive phases of CD56+ T-cell large granular lymphocyte leukemia. Int J Cancer (2004) 0.92
p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res (2002) 0.92
Loss of T-cadherin (CDH13, H-cadherin) expression in cutaneous squamous cell carcinoma. Lab Invest (2002) 0.92
Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. Arterioscler Thromb Vasc Biol (2012) 0.91
Signet-ring stromal tumor of the ovary: an immunohistochemical and ultrastructural study with a review of the literature. Med Mol Morphol (2008) 0.91
Lipoma-like tumor mass probably arising in the retroperitoneal heterotopic pancreas: a previously undescribed lesion. Pathol Int (2004) 0.91
KL-6 is another useful marker in assessing a micropapillary pattern in carcinomas of the breast and urinary bladder, but not the colon. Med Mol Morphol (2009) 0.90
Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression. Clin Cancer Res (2006) 0.90
Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status. Anticancer Res (2008) 0.88
Expression of T-cadherin in Basal keratinocytes of skin. J Invest Dermatol (2002) 0.88
Matrix metalloproteinase-1 expression in splenic angiosarcoma metastasizing to the serous membrane. Int J Clin Exp Pathol (2010) 0.88
Nedd4L modulates the transcription of metalloproteinase-1 and -13 genes to increase the invasive activity of gallbladder cancer. Int J Exp Pathol (2010) 0.88
Conditional VHL gene deletion activates a local NO-VEGF axis in a balanced manner reinforcing resistance to endothelium-targeted glomerulonephropathy. Nephrol Dial Transplant (2011) 0.87
Ultrastructural study of nuclear inclusions immunohistochemically positive for surfactant protein A in pulmonary adenocarcinoma with special reference to their morphogenesis. Med Mol Morphol (2006) 0.87
Overexpression of p53 protein in human tumors. Med Mol Morphol (2012) 0.87
AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells. Mol Cancer Ther (2010) 0.87
Down-regulation of a novel actin-binding molecule, skeletrophin, in malignant melanoma. Am J Pathol (2003) 0.87
Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clin Cancer Res (2005) 0.87
Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and in interstitial pneumonia. Med Mol Morphol (2007) 0.86
Prognostic significance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma. Oncology (2004) 0.86
Three cases of sclerosing lipogranuloma: an immunohistochemical study. Med Mol Morphol (2007) 0.86
Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer (2011) 0.86
Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways. Oncol Rep (2006) 0.86
Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. Cancer Sci (2009) 0.85
Human papillomavirus infection in lung and esophageal cancers: analysis of 485 Asian cases. J Med Virol (2011) 0.85
Overexpression of carbonic anhydrase-related protein XI promotes proliferation and invasion of gastrointestinal stromal tumors. Virchows Arch (2005) 0.85
Detection of Merkel cell polyomavirus in cervical squamous cell carcinomas and adenocarcinomas from Japanese patients. Virol J (2012) 0.85
Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth. Cancer Sci (2008) 0.85
Carbonic anhydrase-related protein VIII promotes colon cancer cell growth. Mol Carcinog (2007) 0.85
Molecular polymerase chain reaction diagnosis of pulmonary mucormycosis caused by Cunninghamella bertholletiae. Respirology (2004) 0.85
Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma. Oncol Rep (2004) 0.85
Association between inducible nitric oxide synthase expression and p53 status in human esophageal squamous cell carcinoma. Oncology (2003) 0.84
Infrequent alteration in the p53R2 gene in human transitional cell carcinoma of the urinary tract. Pathobiology (2004) 0.84
Acute inactivation of the VHL gene contributes to protective effects of ischemic preconditioning in the mouse kidney. Nephron Exp Nephrol (2008) 0.84
Eosinophil infiltration in post-transurethral resection prostatitis and cystitis with special reference to sequential changes of eosinophilia. Med Mol Morphol (2007) 0.83
A rare case of coexistence of pulmonary adenocarcinoma with Langerhans' cell histiocytosis. Med Mol Morphol (2008) 0.83
Expression of cytokeratin 19 in human hepatocellular carcinoma cell lines. Int J Oncol (2002) 0.83
Immunohistochemical localisation of surfactant proteins A and D, and KL-6 in pulmonary alveolar proteinosis. Pathology (2008) 0.83
Differences in the immunolocalization of surfactant protein (SP)-A, SP-D, and KL-6 in pulmonary alveolar proteinosis. Pathol Int (2008) 0.83
Three cases of non-specific interstitial pneumonia associated with primary lung cancer. Intern Med (2004) 0.83
Overexpression of carbonic anhydrase-related protein VIII in human colorectal cancer. J Pathol (2003) 0.82
Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors. Oncol Rep (2004) 0.82
Full-length cytokeratin 8 is released and circulates in patients with non-small cell lung cancer. Tumour Biol (2008) 0.82
Expression of carbonic anhydrase-related protein CA-RP VIII in non-small cell lung cancer. Virchows Arch (2002) 0.82
Immunohistochemical and fluorescence in situ hybridization studies on noninvasive and invasive extramammary Paget's disease. Int J Surg Pathol (2012) 0.82